Oncophage has Phase 3 clinical Phase 3 clinical trials for the treatment of kidney cancer and metastatic melanoma and is currently being evaluated in a Phase 1/2 trial in recurrent glioma.. About Oncophagein April 2008, Oncophage in Russia for the adjuvant treatment of kidney cancer patients at intermediate risk for relapse admitted. In October 2008, Antigenics one MAA to the EMEA requesting approval for Oncophage in an earlier stage, localized renal cell carcinoma. About 19,000lioma. Tumor, Oncophage contains the ‘ antigenic fingerprint’ of the patient’s particular cancer and is designed to make the body’s immune system only cancer cells with this fingerprint reprogram targeted. Oncophage is not affect leave healthy tissue and limit the debilitating side effects traditional traditional cancer treatments such as chemotherapy and radiotherapy.
In October 2008,’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation for BrainAntigenics Inc. announced that Oncophag has a positive recommendation for orphan drug status for the treatment of gliomas by the Committee for Orphan Medical Products issued of the European Medicines Agency . This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product to be marketed in the European Union approved. This is the second indication for which the EMEA has granted Orphan Drug Designation Oncophage -. In April 2005, Oncophage received orphan drug designation in the European Union for the treatment of renal cell carcinoma . Then put Antigenics a Marketing Authorization Application to the EMEA in October 2008, an approval request for Oncophage in an earlier stage, localized renal cell carcinoma.U.S. News and World Report Nashville Peabody College ranking the No. 2 educational school in nation national in 2008.
Furthermore look a significant improvement in one third of men, little drug, something that probable will help them is not clear saw – the medicament or the the drug or the supportive environment is not clear, he said.